Brief: Curevac Starts Phase 1 Clinical Study Of Modified, Omicron-Targeting Covid-19 Vaccine Candidate
18/08/2022 12:16
Aug 18 (Reuters) - CureVac NV 5CV.DE :
* CUREVAC STARTS PHASE 1 CLINICAL STUDY OF MODIFIED,
OMICRON-TARGETING COVID-19 VACCINE CANDIDATE
Source text for Eikon: urn:newsml:reuters.com:*:nEQ8C2zK7a
Further company coverage: 5CV.DE
((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028